Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: GSK pursues M&A to boost pipeline; US decision affects Alzheimer’s candidates; Boehringer Ingelheim’s hopes for Jardiance; Japan rebuilds generic supplies; and a look at key upcoming trial readouts.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 15 April 2022, including: GlaxoSmithKline plc pursues M&A to boost pipeline; US decision affects Alzheimer’s candidates; Boehringer Ingelheim GmbH’s hopes for Jardiance; Japan looks to rebuild generic supplies; and a look at key upcoming trial readouts.
This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Another New Home For Momelotinib As GSK Buys Sierra" - Scrip, 13 Apr, 2022.)
(Also see "Biogen’s Aduhelm Competitors Boosted By Final CMS Coverage Decision" - Scrip, 9 Apr, 2022.)
(Also see "Boehringer Pharma Chief Confident Of Continued Success For Jardiance" - Scrip, 12 Apr, 2022.)
(Also see "A Year's Struggle: How Japan Is Recovering Damaged Generic Supplies After Quality Violations" - Scrip, 12 Apr, 2022.)
(Also see "Four Major Clinical Trial Readouts To Watch Out For In Q2" - Scrip, 12 Apr, 2022.)